Abstract P6-07-32: Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2 positive subtype is associated with the most favorable outcome
| Autor: | Vcg Tjan-Heijnen, Dja Lobbezoo, George F. Borm, Adri C. Voogd, F.P.J. Peters, Najb Peters, A.J. van de Wouw, M.W. Dercksen, F.W.P.J. van den Berkmortel, Rjw van Kampen, Tineke J. Smilde, Jmgh van Riel |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Pathology business.industry Proportional hazards model Cancer Hormone Receptor/HER2 Positive medicine.disease Metastatic breast cancer Primary tumor Breast cancer Hormone receptor Internal medicine Cohort medicine skin and connective tissue diseases business |
| Zdroj: | Cancer Research. 72:P6-07 |
| ISSN: | 1538-7445 0008-5472 |
| DOI: | 10.1158/0008-5472.sabcs12-p6-07-32 |
| Popis: | Background: In early breast cancer the different subtypes and their prognostic relevance are well known, contrary to the knowledge on prognostic relevance of subtypes in metastatic breast cancer. This study presents survival estimates after diagnosis of distant metastases of breast cancer subtypes in a recent cohort in which the treatment is representative of current clinical practice. Patients and methods: All patients diagnosed with metastatic breast cancer in one of eight participating hospitals in the South-East part of the Netherlands between 2007–2009 were included and all medical charts were reviewed. Patients were categorized in 4 subtypes based on the hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status of the primary tumor; HR positive/HER2 negative, HR positive/HER2 positive, HR negative/HER2 positive and triple negative (TN). Metastatic survival was estimated using the Kaplan-Meier product-limit method. Cox proportional hazards model was used to determine the prognostic impact of breast cancer subtype, adjusted for possible confounders. Results: A total of 815 patients were included; the HR+/HER2− subtype comprising 66%, the HR−/HER2+ subtype 8%, the TN subtype 15% and the HR+/HER2+ subtype 11% of patients. The four subtypes were associated with different metastatic survival times; the HR+/HER2+ subtype was associated with the best metastatic survival (median, 32.9 months), compared to 22.1 months for the HR+/HER2− subtype, 19.5 months for the HR−/HER2+ subtype and 7.7 months for the TN subtype. Aside from subtype, other prognostic factors of metastatic survival were site of metastases and metastatic-free interval. Conclusion: Of the four subtypes, the HR+/HER2+ subtype was associated with the most favorable outcome, in terms of metastatic survival. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P6-07-32. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|